Mangoceuticals, Inc. — Form 10-Q Summary
Business context and reporting period
Mangoceuticals, Inc. filed an unaudited Form 10-Q for the quarter and six months ended June 30, 2023. The company markets the Mango ED compounded erectile-dysfunction product through its online telemedicine platform, MangoRx.com. Revenue generation began in November 2022. The company is a smaller reporting company and emerging growth company; its common stock trades on Nasdaq under MGRX.
Financial performance and position
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 | Comparable prior period |
|---|---|---|---|
| Revenue | $141,237 | $241,959 | $0 |
| Gross profit | $87,130 | $144,329 | $0 |
| Gross margin | 61.7% | 59.7% | Not applicable |
| General and administrative expense | $2,379,388 | $4,995,712 | $327,902 and $346,612 |
| Loss from operations | $(2,292,258) | $(4,851,383) | $(327,902) and $(346,612) |
| Net loss | $(2,284,025) | $(4,844,910) | $(329,485) and $(349,084) |
| Basic and diluted loss per share | $(0.14) | $(0.33) | $(0.04) in each comparable period |
- Operating expenses substantially exceeded gross profit. The filing does not provide a non-GAAP EBITDA measure.
- Major expense drivers included stock-based compensation and stock issued for services, advertising and marketing, IPO-related legal and placement-agent costs, payroll, consulting, accounting and software development.
- Advertising and marketing expense was $284,366 for the quarter and $912,997 for the six months. The company reported no income tax expense.
- Cash and cash equivalents were $2.95 million at June 30, 2023, compared with $682,860 at December 31, 2022. Working capital was approximately $2.8 million.
- Net cash used in operating activities was $3.59 million; investing cash use was $3,519; and financing cash provided was $5.86 million. Financing inflows primarily consisted of $5.0 million of IPO proceeds and approximately $1.02 million from warrant exercises.
- Total assets were $3.30 million and total liabilities were $293,873. Stockholders’ equity was $3.00 million, while accumulated deficit was $6.86 million.
- At quarter-end, the company had no outstanding notes payable or related-party notes payable. Remaining liabilities consisted primarily of accounts payable, payroll taxes and operating lease liabilities totaling $157,543.
Material changes versus the prior comparable period
- Revenue increased from zero to $141,237 for the quarter and $241,959 for the six-month period as the company moved from pre-revenue operations to early commercialization.
- Despite generating revenue, the six-month net loss increased to $4.84 million from $349,084, primarily because of substantially higher operating expenses and public-company costs.
- Shares outstanding increased to 16,714,500 at June 30, 2023 from 13,365,000 at December 31, 2022. The increase reflected the IPO, warrant exercises and shares issued for services.
- The company completed its March 2023 IPO of 1.25 million shares at $4.00 per share, generating approximately $4.35 million of net proceeds after underwriting discounts and offering costs.
- Holders exercised 1,024,500 private-placement warrants during the six months, generating approximately $1.02 million of cash. Approximately 1,063,000 warrants remained outstanding at quarter-end, including 975,500 warrants exercisable at $1.00 per share and 87,500 IPO-related warrants exercisable at $5.00 per share.
- Related-party advances of $89,200 were repaid in April 2023, and the equipment note payable was fully repaid. The filing recorded an $8,233 reversal of previously imputed related-party interest.
Outlook, commentary, risks and unusual items
- Management stated that existing cash, expected revenue and current spending levels were expected to fund operations for the next 12 months. Additional capital may be required for expansion or acquisitions and could involve debt, equity dilution or unfavorable terms.
- The company plans to continue marketing Mango ED, improve its technology platform, expand men’s health and wellness offerings, and evaluate acquisitions. No specific revenue, earnings or margin guidance was provided.
- The Mango ED product is compounded and is not, and will not be, FDA-approved. The company relies on the Section 503A compounding exemption and acknowledged that regulators could determine the product is noncompliant, an impermissible copy of an approved product, or otherwise subject to restrictions.
- The company relies on Epiq Scripts, a pharmacy 51% owned and controlled by CEO and Chairman Jacob Cohen, for compounding and pharmacy services. Epiq Scripts was licensed in 45 states and the District of Columbia at the filing date, limiting geographic coverage until additional licenses are obtained.
- Related-party transactions include pharmacy services, prepaid amounts to Epiq Scripts, and prior financing. These arrangements create potential conflicts of interest and may not provide terms equivalent to arm’s-length transactions.
- The company has a limited operating history, recurring losses and limited revenue. Its independent registered public accounting firm included an explanatory paragraph in its December 31, 2022 report.
- Other key risks include product liability and safety claims, changing healthcare and telehealth regulations, privacy and cybersecurity incidents, dependence on third-party physicians and shipping providers, competition, customer acquisition costs, inflation and access to capital.
- Management reported no current material litigation, no material subsequent events requiring disclosure, and effective disclosure controls as of June 30, 2023.
- Stock-based compensation and equity issued for services were significant and reduced cash usage but increased dilution. The company recognized $1.09 million of common stock issued for services and $128,542 of option-related stock compensation in operating cash-flow reconciliation for the six months.
Important facts for investors to verify
- Whether revenue growth can scale sufficiently to offset the company’s substantial marketing, compensation, technology and public-company expenses.
- The company’s ongoing cash burn, accumulated deficit and the timing or terms of any future financing.
- The regulatory status of the compounded Mango ED product, including compliance with Section 503A and applicable state pharmacy and telehealth laws.
- Epiq Scripts’ licensing coverage, operational capacity and the economic terms of the related-party pharmacy agreement.
- The potential dilution from 1.4 million outstanding options and approximately 1.063 million outstanding warrants, as well as future equity issued for services or financing.
- Nasdaq listing compliance, particularly the company’s stockholders’ equity, bid price and other continued-listing requirements.
- The accuracy and comparability of related-party expense, prepaid and service arrangements, including the company’s reported cost of revenues paid to Epiq Scripts.